Listing in computer and paper form in accordance with 37 C.F.R. §1.821-1.825. The content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same and do not include new matter.

Applicants respectfully request consideration of the following amendments.

IN THE SPECIFICATION

In the Experimental Details, please amend the paragraph on page 59, line 20 through page 60, line 12 as follows:

Electrophoretic Mobility Shift Assay (EMSA). Nuclear extracts were prepared as described (25). Briefly, binding reactions were performed in 10 or 20 ml reaction mixtures containing 1-3 mg of nuclear extracts from control or differentiation inducer treated HO-1 cells. The binding buffer contained 12 mM HEPES (pH 7.9), 5 mM $MgCl_2$, 60 mM KCl, 0.6 mM EDTA, 0.5 mM dithiothreitol, 1 mg of poly (dI-dC), 10% glycerol. The region corresponding to the putative AP-1 and C/EBP binding sites present between NdeI and NheI restriction enzyme sites was PCR amplified using flanking primers, 5'-AGGCTGGATTTG GCTTGTGAC-3' (Sense) (SEQ ID NO:3) and 5'-CTGTTTAATCCAGCACTTCCC-3' (Antisense) (SEQ ID NO:4). The PCR product was column purified (Qiagen), end labeled with γ-^{32}P [ATP] and 1500 cpm of double stranded DNA were used per binding reaction. Binding reactions were performed at RT for 30 min. Reactions were then loaded onto a 4% polyacrylamide gel and electrophoresed at 4° C at 100 V in 0.25X Tris-borate-EDTA as described (26, 27). Competition and supershift

reactions were identical to those described above, except a 10-100 fold excess of AP-1 or C/EBP wild type or mutant oligonucleotides (AP-1/WT; 5'–CGCTTGATGACTCAGCCGGAA-3'), (SEQ ID NO: 5), (C/EBP/WT; 5'–TGCAGATTGCGCAATCTGC A-3'), (SEQ ID NO. 6), (AP-1/MT; 5'–CGCTTGATGACTTGGCCGGAA-3') (SEQ ID NO:7) and C/EBP (C/EBP/MT; 5'–TGCAGAGACTAGTCTCTGCA-3') (SEQ ID NO:8) or 1-5 μg of either anti-cJun/AP-1 or anti-C/EBP-β antibody (Santa Cruz) were added to the binding reactions along with the labeled probe and reactions were incubated for 30 min at RT prior to electrophoresis. The gels were then dried and exposed to X-ray film.

B1 CONT.

Please **delete** the sequence listing and substitute, therefore, the attached substitute sequence listing.

REMARKS

In response to the Office Communication, mailed on August 16, 2001, Applicants submit the following Response to Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicants submit herewith a substitute Sequence Listing in computer and paper form in accordance with 37 C.F.R. §1.821-1.825. A copy of the Office Communication is enclosed.